Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls
This article was originally published in The Pink Sheet Daily
Executive Summary
West Coast contractor Palmetto issues draft proposal establishing a"non-coverage" policy for molecular tests not explicitly covered by Palmetto or a national CMS directive.